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Nowadays, several screening strategies are available to prevent cervical cancer, but inadequate resources, sociocultural barriers,
and sampling issues impede their success in low-income countries. To overcome these issues, this study aimed to evaluate the
performance of human papillomavirus (HPV) testing from dried urine spots (DUS). Eighty-eight urine samples (including 56HPV
DNA positive specimens) were spotted on filter paper, dried, and stored in paper-bags. HPVDNAwas detected from the DUS after
1 week and 4 weeks of storage using a polymerase chain reaction (PCR) assay. The sensitivity, specificity, and concordance of the
DUS-basedHPV test were evaluated by comparing the results with those ofHPV testing on fresh urine samples as the gold standard.
The sensitivity of the test was 98.21% (95%CI: 90.56–99.68) for DUS stored for 1 week and 96.42% (95%CI: 87.88–99.01) for DUS
stored for 4 weeks. The specificity was 100% (95%CI: 89.28–100) at both time points. The concordance between DUS and fresh
urine HPV testing was “almost perfect” using the 𝜅 statistic. These preliminary data suggest that a DUS-based assay could bypass
sociocultural barriers and sampling issues and therefore could be a suitable, effective tool for epidemiological surveillance and
screening programs, especially in low-income countries.
1. Introduction
Cervical cancer is a relevant public health problem for
women worldwide, being the third most frequent cancer
and the fourth most common cause of death from cancer
in women [1, 2]. Overall, the World Health Organization
(WHO) estimates that there are 530,000 new cases of cervical
cancer each year and more than 270,000 deaths, with 85%
of deaths occurring in low- and middle-income countries
[3]. All cervical cancers can be attributable to a sexually
transmitted infection (STI) that is caused by the human papil-
lomavirus (HPV). HPV infections usually clear up without
any intervention within a few months after acquisition, and
approximately 90% of infections clear up within two years. A
small proportion of infections with certain types of HPV can
persist and progress to cancer [3].
HPVs are DNA viruses that are grouped into cutaneous
and mucosal types according to their infection site and fur-
ther subdivided into high-risk (HR) and low-risk (LR) types,
depending on their association with disease malignancy. The
International Agency for Research on Cancer (IARC) has
included 25 types of HPV in the high-risk clade (HR-clade)
by subdividing them into three groups [4]. HPV types 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 are classified in
group 1 as “carcinogenic to humans,” while groups 2A and 2B
include the “probably carcinogenic to humans” and “possibly
carcinogenic to humans” genotypes, respectively. HPV16 and
HPV18 are the two most common HR types in cervical
cancer, causing approximately 70% of all cases worldwide [4].
Different types of screening for cervical cancer are now
available, such as the conventional cytology test (Pap test)
and liquid based cytology (LBC), visual inspectionwith acetic
acid (VIA), and HPV testing for HR-HPV from cervical
brush. These types of screening require adequate financial
resources, a developed infrastructure, trained labour, and
surveillance mechanisms for screening, investigating, treat-
ing, and following up on targeted women [5, 6]. Moreover,
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women’s educational levels, misconceptions, and prejudices
are barriers to access and to the success of cervical cancer
prevention programs in low-resource countries. Due to these
difficulties, the disease is often identified in the late stage,
resulting in higher rates of cervical cancer incidence and
mortality [7–9].
Alternative tools that can overcome these problems could
improve screening coverage and reach the female population
at risk in developing countries.
The use of HPV testing on urine, a noninvasive and easy-
to-collect sample, could bemore attractive to women because
it bypasses medical examination, as well as sociocultural and
religious implications. The correlation between the detection
of HPV in urine and cervical samples has been reported in
several studies in the literature [10–12]. In addition, HPV
DNA testing is more sensitive than cytology for detecting
high-grade cervical intraepithelial neoplasia (CIN), and it
would provide an automated and objective assay, which
would improve quality control [13].
However, urine samples require restrictive conditions for
storage and transportation, especially when samples must
be transported over large distances in a warm climate. This
factor is particularly relevant in low-income countries where
analysis laboratories can be located far away from the rural
areas where women live. An alternative method of sample
collection is the use of dried urine spots (DUS), that is, a
urine sample spotted on blotting paper, which allows for
stabilization by drying. This approach has logistical benefits
because DUS are small and easily transported and the
specimens can be stored at room temperature.
DUS sample collection solves several problems associated
with the sampling and storage of fresh urine samples. There-
fore, the DUS approach is particularly interesting, especially
in developing countries, even considering that dried spots
on filter paper can be successfully used for the detection of
various infectious agents, as well as metabolic and genetic
diseases [14–16].
Few studies have evaluated the use of dried samples on
filter paper for the detection of HPV infection, and these
investigations examined exclusively cervical brush samples
[17–19]. No data are presently available about the use of urine
samples on this type of medium.
Thus, the aim of this study was to evaluate the perfor-
mance of HPV testing from DUS and to compare the results
obtained with those from paired fresh urine samples.
2. Materials and Methods
2.1. Sample Collection. Urine samples were obtained from
88 immigrant women (median age: 34 years; interquartile
range (IQR): 28–43 years) who attended NAGA Onlus in
Milan, Italy, between June 2012 and December 2013 and
were included in a large epidemiological study on HPV and
Chlamydia trachomatis infections [20]. All of the women
provided informed consent for further anonymous research
testing on the residual samples. Ethics approval was obtained
from the Ethics Committee of the University of Milan, Italy.
Of the urine samples, 56/88 (63.6%) were HPV DNA
positive and 32 (36.3%) were HPV DNA negative. Of the
HPVDNA positive samples, 40/56 (71.4%) were sustained by
single infections (24 belonging to HR-clade genotypes and 16
to LR genotypes) and 16/56 (28.6%) were caused by multiple
infections (4 were caused by LR genotypes and 12 by at least 1
genotype of the HR-clade).
2.2. Sample Preparation. Each 400𝜇L urine sample was sub-
divided into eight 50 𝜇L aliquots that were each spotted on
preprinted circles on a piece of filter paper (Mascia Brunelli,
Italy).TheDUSfilter paperswere dried for 3 h and then stored
in paper bags in a dry location at room temperature (RT; 25–
30∘C) for either 1 week or 4 weeks until the analyses took
place.The analyses were carried out at the Laboratories of the
Department of Biomedical Sciences for Health, University of
Milan, Italy.
2.3. Nucleic Acids Extraction. Four preprinted circles were
punched or cut out from each piece of DUS filter paper
using a sterile single-cut paper-punching machine or a new
sterile scalpel blade.The circles were transferred into a 1.5mL
tube containing 1mL of NucliSENS Lysis Buffer (bioMe´rieux,
Lyon, France) and incubated on a roller mixer for 30
minutes at RT. Then the tube was centrifuged for 15 s at
1500×g. The lysate, with a volume of approximately 750𝜇L,
was extracted using the commercial NucliSENS EasyMAG
method (bioMe´rieux, Lyon, France), according to the manu-
facturer’s instructions.The nucleic acids were eluted in 100𝜇L
of the NucliSENS elution buffer.
The concentration of the extracted DNA was evaluated
using a spectrophotometer (NanoDrop 2000c,ThermoFisher
Scientific Inc., Wilmington, DE, USA). The quality of DNA
was validated by detection of a 268 bp fragment of the house-
keeping beta-globin gene using an in-house polymerase chain
reaction (PCR) assay [21].
2.4. HPV DNA Detection. HPV DNA was detected using
an in-house nested-PCR assay based on the amplification
of a 150 bp open reading frame late gene 1 (ORF L1) frag-
ment. The nested-PCR assay was performed using a two-
step amplification to either increase sensitivity or mitigate
the inhibitory effect of substances potentially present in
the sample. Every PCR reaction included positive (HPV-
16 positive cells, Caski) and negative (water) controls. Strict
laboratory precautions and quality assurance/quality control
measures were followed to avoid cross contamination and
carry over PCR. ELSI F/ELSI R primers were used for the
first cycle of amplification and GP5+/GP6+ primers were
used for the nested reaction, as previously described [11, 22].
The amplification products were visualized by means
of electrophoresis analysis on 2% agarose gels containing
ethidium bromide (0.5mg/mL).The amplified products were
compared with molecular weight standards (DNAMolecular
Weight, Marker 100, Sigma-Aldrich, St. Louis, MO, USA).
2.5. HPV Genotyping. HPV DNA positive DUS isolates
were genotyped using INNO-LiPA HPV Genotyping Extra
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Table 1: HPV DNA detection in fresh urine and DUS samples.
Storage time HPV DNA Number of fresh urine samples Number of DUS samples % (95% CI) 𝜅 statistic
1 week Positive 56 55 98.21 (90.56–99.68) 0.98
Negative 32 32 100 (89.28–100) 1
4 weeks Positive 56 54 96.42 (87.88–99.01) 0.95
Negative 32 32 100 (89.28–100) 1
(Fujirebio Italia, Rome, Italy), a line probe assay based on
the principle of reverse hybridization, according to themanu-
facturer’s instructions.The resulting line patterns allowed for
identification of 28 different HPV genotypes: 6, 11, 16, 18, 26,
31, 33, 35, 39, 40, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69,
70, 71, 73, 74, and 82.
2.6. Statistical Analysis. The sensitivity and specificity of
HPV testing fromDUSwere evaluated in comparison toHPV
testing from fresh urine samples as the gold standard. These
results were presented as percentages with 95% confidence
intervals (95% CIs). Proportions (95% CI) were calculated
using the Wilson score model by the OpenEpi statistical
program (version 3.01), which is available online [23].
To determine the proportion of agreement between
DUS and fresh urine testing, Cohen’s unweighted kappa (𝜅)
statistic was calculated by dividing the difference between
the observed proportion of agreement and the expected
proportion of agreement by 1 minus the expected proportion
of agreement.The concordancewas defined as “poor” (𝑘 = 0),
“slight” (0.01 ≤ 𝑘 ≤ 0.20), “fair” (0.21 ≤ 𝑘 ≤ 0.40),
“moderate” (0.41 ≤ 𝑘 ≤ 0.60), “substantial” (0.61 ≤ 𝑘 ≤ 0.80),
“almost perfect” (0.81 ≤ 𝑘 < 1.00), or “perfect” (𝑘 = 1.00).
3. Results
DNA was successfully extracted from all of the DUS samples
stored at RT for either 1 week or 4 weeks.The evaluated DNA
concentrations ranged from 6.4 to 50.2 ng/𝜇L for 1 week of
DUS storage and from 7 to 30.8 ng/𝜇L for 4 weeks of DUS
storage. The housekeeping beta-globin gene was amplified
from all DUS samples, confirming the suitability of the DNA
extraction method.
3.1. Detection of HPV DNA from DUS after 1 Week or 4 Weeks
of Storage. Of the 56 DUS samples prepared fromHPVDNA
positive fresh urine, 55/56 (98.21%, 95% CI: 90.56–99.68)
testedHPVDNApositive after 1 week. In contrast, HPVDNA
was detected in 54/56 (96.42%, 95% CI: 87.88–99.01) of the
DUS samples after storage for 4 weeks.
The DUS sample that tested HPV DNA negative after
both 1 and 4 weeks of storage was prepared from an HPV-
72 (LR HPV) infected urine sample. The other DUS that
tested HPV DNA negative only after 4 weeks of storage was
prepared from an HPV-56 (HR HPV) infected urine sample.
All DUS prepared using HPV DNA negative urine sam-
ples tested negative for HPV DNA.
The sensitivity of the HPV DNA test in DUS at 1 and 4
weeks was 98.21% (95% CI: 90.56–99.68) and 96.42% (95%
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Figure 1: Distribution of HPV genotypes in fresh urine samples and
in corresponding DUS samples after four weeks of storage.
CI: 87.88–99.01), respectively. The specificity for the test was
100% (95% CI: 89.28–100) after both 1 week and 4 weeks
of storage. The proportion of agreement between the DUS
and fresh urine tests was “almost perfect” (𝜅 statistic ≥ 0.81)
(Table 1).
3.2. HPV Genotyping. Of the 40 DUS prepared from fresh
urine samples of women infected by a single HPV genotype,
38 (95%) tested HPV DNA positive after four weeks of
storage. All amplified fragments from the DUS were properly
genotyped, and the distribution of HPV genotypes matched
across the two sample types (Figure 1). The distribution of
HR-clade and LR HPV genotypes was similar across the
paired samples. In particular, 23 HPV DNA positive DUS
were sustained by HR-clade genotypes and 15 were caused by
LR genotypes.
4. Discussion
To our knowledge, this is the first report of HPV detection
from urine samples stored on filter paper. The quantity and
the quality of DNA extracted from DUS were comparable
to those obtained by standard collection from fresh urine,
as estimated by the spectrophotometric readings and the
detection of the housekeeping beta-globin gene using an in-
house PCR assay. Accordingly, the high molecular weight
DNA extracted from DUS samples is sufficient to perform
molecular assays, either traditional or high throughput.
The data obtained showed an elevated concordance
between HPV DNA detection in DUS and fresh urine sam-
ples. Cohen’s unweighted kappa values were very high, indi-
cating an “almost perfect” agreement.
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These preliminary data support the use of DUS as simple,
rapid, and safe sampling for HPV DNA detection and geno-
typing by using molecular tests, such as PCR and line probe
assay based on the principle of reverse hybridization. Fur-
thermore, the use of DUS strengthens the already recognized
advantages of urine samples. Collection of these noninvasive
specimens is more acceptable and can bypass the ethical,
social, and religious barriers of speculum exams for the
collection of conventional cervical brush [7, 8, 11].
Moreover, drying urine samples on filter paper allows the
DNA to be protected from degradation for a long period,
as shown by the high percentage (96.4%) of HPV DNA
positive samples detected after four weeks of storage at room
temperature.
Due to the introduction and increasing availability of
novel and powerful high-throughputmolecular technologies,
the optimization ofmethods for biological samples collection
and storage has become a critical issue.These results highlight
the potential use of DUS samples as an alternative means of
biobanking, avoiding the high costs and logistical problems
associated with the storage and transportation, especially
where a cold chain is absent [19, 24]. Finally, DUS have a small
size and can be easily mailed to a reference laboratory.
5. Conclusions
HPV testing from DUS showed an elevated sensitivity and
specificity and a high concordance rate compared to HPV
testing from fresh urine samples. These preliminary data
suggest that a DUS-based assay could bypass sociocultural
barriers and sampling issues. This approach could be a
suitable and effective tool for epidemiological surveillance
and screening programs, especially in low-income countries.
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